Diabetes and infections-hepatitis C: Is there type 2 diabetes excess in hepatitis C infection?

Current Diabetes Reports

Volumn 13, Issue 3, 2013, Pages 428-434

  Naing, Cho ^a   Mak, Joon Wah ^a   Wai, Nyunt ^a   Maung, Mala ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

ER; HCV protein; Hepatitis C infection; Insulin resistance; IRS1 2; Peroxisome proliferator activated receptors ; TNF alpha; Type 2 diabetes

Indexed keywords

ALPHA ACTIN; CARBON MONOXIDE; CYTOKINE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 4; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; GLYCEROL KINASE; HEPATITIS B VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; ICOSANOID; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 6; NITRIC OXIDE; NONSTRUCTURAL PROTEIN 5A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; RETINOID X RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; VIRUS PROTEIN;

APOPTOSIS; ARTICLE; CYTOKINE RELEASE; CYTOPATHOGENIC EFFECT; DISEASE ASSOCIATION; DISEASE COURSE; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME INHIBITION; GLUCOGENESIS; GLUCONEOGENESIS; HEPATITIS B; HEPATITIS C; HUMAN; INFLAMMATION; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SIGNALING PATHWAY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PREVALENCE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UBIQUITINATION; VACCINATION; VIRUS REPLICATION; VIRUS TRANSMISSION; BIOLOGICAL MODEL; COMPLICATION; DIABETES MELLITUS, TYPE 2; PUBLIC HEALTH; RISK FACTOR;

DIABETES MELLITUS, TYPE 2; HEPATITIS B; HEPATITIS C; HUMANS; MODELS, BIOLOGICAL; PUBLIC HEALTH; RISK FACTORS;

EID: 84877774406     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-013-0370-3     Document Type: Article

References (60)

1. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol. 1994;1135-9.
2. Alexander GJM. An association between hepatitis C virus and type 2 diabetes: what is the connection? Ann Intern Med. 2000;133:650-2.
3. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29:328-33. (Pubitemid 29088433)
4. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Hepatology. 2001;33:1554. (Pubitemid 32496997)
5. Lecube A, Hernandez C, Genesca J, Simo R. Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis. Diabetes Care. 2006;29:1140-9. (Pubitemid 44115262)
6. Mangia A, Schiavone G, Lezzi G, Marmo R, Bruno F, Villani MR, et al. HCV and diabetes mellitus: evidence for a negative association. Am J Gastroenterol. 1998;93:2363-7. (Pubitemid 29018539)
7. Howard AA, Klein RS, Schoenbaum EE. Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users. Clin Infect Dis. 2003;36:1318-23. (Pubitemid 36629943)
8. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49:831-44. This systematic review, based on both prospective and retrospective studies, provided evidence on excess risk of T2D in HCV infection than in comparison with non-infected controls. Also, it was observed an excess risk in HICV infection than HBV infection, suggesting a potential direct viral role in promoting DM risk.
9. Naing C, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol. 2012;18:1642-51. This meta- analysis of 17 observational studies assessing the relationship between HCV infection and T2D. The comparisons were done between HCV infected and not infected, and HCV infected and HBV infected. The findings support the association between HCV and T2D. However, the direction of association remains to be determined.
10. American Diabetes Association. Diagnosis and classification of Diabetes Mellitus. Diabetes Care. 2010;33 Suppl 1:S62-9. This document addresses comprehensive information on both etiologic classification and diagnostic criteria for diabetes mellitus.
11. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840-8. This article provides possible explanations between HCV and T2D based on animal model studies. (Pubitemid 38298332)
12. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant. 2005;5(10):2433-40.
13. Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia. 2001;44:914-22. (Pubitemid 32642465)
14. Raj SM, Howson JM, Walker NM, Cooper JD, Smyth DJ, Field SF, et al. No association of multiple type 2 diabetes loci with type 1 diabetes. Diabetologia. 2009;52:2109-16.
15. Verbeeten KC, Elks CE, Daneman D, Ong KK. Association between childhood obesity and subsequent type 1 diabetes: a systematic review and meta-analysis. Diabet Med. 2011;28:10-8.
16. CDC (Centers for Disease Control and Prevention). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-Related Chronic Disease. The MMWR series. 1998;47:19. http://www.cdc.gov/mmwr/PDF/RR/ RR4719.pdf
17. McHutchison JG. Understanding hepatitis C. Am J Manag Care. 2004;10(Suppl):S21-9.
18. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777-82. (Pubitemid 30118650)
19. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-62. (Pubitemid 29384163)
20. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52. (Pubitemid 32634271)
21. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31:1090-101.
22. Panlilio AL, Shapiro CN, Schable CA, Mendelson MH, Montecalvo MA, Kunches LM, et al. Serosurvey of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among hospital-based surgeons. Serosurvey Study Group. J Am Coll Surg. 1995;180:16-24.
23. Gershon RR, Sherman M, Mitchell C, Vlahov D, Erwin MJ, Lears MK, et al. Prevalence and risk factors for blood borne exposure and infection in correctional healthcare workers. Infect Control Hosp Epidemiol. 2007;28:24-30. (Pubitemid 46219221)
24. Hall CS, Charlebois ED, Hahn JA, Moss AR, Bangsberg DR. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med. 2004;19:357-65. (Pubitemid 38530507)
25. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133:592-9.
26. Imazeki F, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int. 2008;28:355-62. (Pubitemid 351279583)
27. Balbi M, Donadon V, Ghersetti M, et al. Alcohol and HCV chronic infection are risk cofactors of type 2 diabetes mellitus for hepatocellular carcinoma in Italy. Int J Environ Res Public Health. 2010;7:1366-78. This is a retrospective, case-control study with 465 consecutive patients with HCC, assessing the effect of alcohol consumption and HCV infections alone and as co-factors of diabetes mellitus, on the risk of HCC in Italian patients. Interestingly, this study examined whether the combined effect of 2 factors on HCC was greater than the sum of the individual effects, using the Rothman's synergy index method.
28. Qureshi H, Ahsan T, Mujeeb SA, Jawad F, Mehdi I, Ahmed W, et al. Diabetes mellitus is equally frequent in chronic HCV and HBV infection. J Pak Med Assoc. 2002;52:280-3.
29. Negro F, Alaei M. Hepatitis C virus and type 2 diabetes. World J Gastroenterol. 2009;15:1537-47.
30. Antonelli A, Ferri C, Fallahi P, Sebastiani M, Nesti C, Barani L, et al. Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology. 2004;43:238-40. (Pubitemid 38219683)
31. Chehadeh W, Abdella N, Ben-Nakhi A, Al-Arouj M, Al-Nakib W. Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection. J Gastroenterol Hepatol. 2009;24:42-8.
32. White MF, Shoelson SE, Keutmann H, Kahn CR. A cascade of tyrosine autophosphorylation in the beta-subunit activates the insulin receptor. J Biol Chem. 1988;263:2969-80. (Pubitemid 18062952)
33. Kappel CR, Kretzmann NA, Alvares-da-Silva MR. IRS-1 expression in hepatic tissue and leukocytes in chronic hepatitis C virus infected patients: a comparative study. Int J Hepatol. 2012;2012:698905. doi: 10.1155/2012/698905.
34. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling. Am J Pathol. 2004;165:1499-508. This article addressed an empirical study reporting the presence of severe insulin resistance in noncirrhotic patients with HCV infection more than in patients with other hepatobiliary diseases. (Pubitemid 39435150)
35. Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007;102:570-6. (Pubitemid 46328143)
36. Bernsmeier C, Duong FH, Christen V, Pugnale P, Negro F, Terracciano L, et al. Virus-induced over-expression of protein phosphatase 2A inhibits insulin signaling in chronic hepatitis C. J Hepatol. 2008;49:429-40.
37. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI-3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology. 2003;38:1384-92. (Pubitemid 37466964)
38. Yessoufou A, Wahli W. Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Med Wkly. 2010;140:w13071. doi: 10.4414/smw.2010.13071.
39. Bardot O, Aldridge TC, Latruffe N, Green S. PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene. Biochem Biophys Res Commun. 1993;192:37-45. (Pubitemid 23205265)
40. Eslam M, Khattab MA, Harrison SA. Peroxisome proliferator-activated receptors and hepatitis C virus. Ther Adv Gastroenterol. 2011;4:419-31. This review article explained the details about the role of PPARs in glucose homeostasis.
41. Patsouris D, Mandard S, Voshol PJ, et al. PPARα governs glycerol metabolism. J Clin Invest. 2004;114:94-103.
42. Jiang G, Dallas-Yang Q, Li Z, Szalkowski D, Liu F, Shen X, et al. Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPAR gamma agonists. Diabetes. 2002;51:2412-9. (Pubitemid 34827389)
43. Dharancy S, Malapel M, Perlemuter G, et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology. 2005;128:334-42. (Pubitemid 40431087)
44. de Gottardi A, Pazienza V, Pugnale P, Bruttin F, Rubbia-Brandt L, Juge-Aubry CE, et al. Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther. 2006;23:107-14. (Pubitemid 43381173)
45. Clément S, Pascarella S, Negro F. Hepatitis C virus infection: molecular pathways to steatosis, insulin resistance, and oxidative stress. Viruses. 2009;1:126-43.
46. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840-8. (Pubitemid 38298332)
47. Kmieć Z. Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol. 2001;161:1-151.
48. Costantini S, Castello G, Colonna G. Human cytokinome: a new challenge for systems biology. Bioinformation. 2010;5:166-7.
49. Costantini S, Capone F, Guerriero E, Marfella R, Sorice A, Maio P, et al. Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection. PLoS One. 2012;7:e39486. This is a primary study assessing comparative profile of cytokines in patients with T2D, chronic hepatitis C, chronic hepatitis C related T2D, or chronic hepatitis C related cirrhosis, and healthy control subjects. This article reported specific markers for the different disease staging.
50. Oliveira CP, Kappel CR, Siqueira ER, et al. Effects of hepatitis C virus on cardiovascular risk in infected patients: a comparative study. Int J Cardiol. 2011. doi: 10.1016/j.ijcard.2011.07.016.
51. Zekri ARN, Ashour MSE, Hassan A, Alam El-Din MA, El-Shehaby AMR, Abu-Shady MA. Cytokine profile in Egyptian HCV genotype-4 in relation to liver disease progression. World J Gastroenterol. 2005;11:6624-30. (Pubitemid 43072701)
52. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance, and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest. 2002;(Suppl 3):24-34. (Pubitemid 41704997)
53. Hotamisligil GS. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes. 2005;(Suppl 2):S73-8. (Pubitemid 43343334)
54. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004;306:457-61. (Pubitemid 39372439)
55. Christen V, Treves S, Duong FH, Heim MH. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology. 2007;46:558-65. (Pubitemid 47344792)
56. Romero-Gómez M, Del Mar VM, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636-41. (Pubitemid 40585366)
57. Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol. 2008;48:721-7.
58. Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol. 2009;50:712-8.
59. Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol. 2008;48:28-34. (Pubitemid 350191982)
60. Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol. 2010;105:1970-7.